Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL001 vs BAT in CML-CP after ≥2 TKIs (China)
CTR20212457Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asciminib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: MMR rate with asciminib at Week 24. Started Sep 2021; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20212457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212457.